Peptides Similar to Cagrilintide

Peptides Related to Cagrilintide#

Cagrilintide occupies a unique position in the anti-obesity therapeutic landscape as a long-acting amylin receptor agonist. It can be compared to several classes of related peptide therapies: amylin analogs (pramlintide), GLP-1 receptor agonists (semaglutide, liraglutide), dual incretin agonists (tirzepatide), and the CagriSema combination itself. Understanding these comparisons is essential for appreciating the therapeutic rationale and competitive positioning of cagrilintide.

Semaglutide (GLP-1 Receptor Agonist)#

Semaglutide (marketed as Wegovy for obesity and Ozempic for type 2 diabetes) is the most important comparator for cagrilintide, both as a competitor and as a combination partner. Semaglutide is a long-acting GLP-1 receptor agonist that produces approximately 15 to 17% weight loss when used at the 2.4 mg weekly dose.

The mechanistic comparison is instructive. Semaglutide acts primarily through GLP-1 receptors in the hypothalamic arcuate nucleus and paraventricular nucleus, reducing appetite through modulation of POMC/CART and NPY/AgRP neuron activity. Cagrilintide acts through amylin receptors in the area postrema and nucleus of the solitary tract, engaging brainstem satiety circuits. These are anatomically and pharmacologically distinct pathways that converge on downstream circuits controlling food intake and energy balance.

The combination of cagrilintide with semaglutide (CagriSema) produces weight loss of approximately 20 to 25% in phase 3 trials, substantially exceeding what semaglutide achieves alone. This clinical result validates the hypothesis that engaging multiple appetite-regulatory pathways simultaneously produces greater therapeutic benefit than maximizing a single pathway.

From a development standpoint, semaglutide has the significant advantage of established regulatory approval, extensive real-world safety data, and widespread clinical adoption. Cagrilintide as a standalone agent would need to demonstrate a compelling clinical profile to compete with established GLP-1 agonists; its primary clinical path is as the amylin component of CagriSema.

Tirzepatide (Dual GIP/GLP-1 Agonist)#

Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that produces approximately 20 to 22% weight loss at the highest approved dose. It represents the primary clinical competitor for CagriSema.

The mechanistic difference between the two approaches is fundamental. Tirzepatide achieves dual-mechanism activity through a single molecule that activates two incretin receptors (GIP-R and GLP-1R). CagriSema achieves multi-mechanism activity through two separate molecules acting on different receptor systems (amylin receptors plus GLP-1 receptors). The pathways engaged are largely non-overlapping: tirzepatide acts through incretin signaling, while CagriSema adds amylin receptor-mediated brainstem appetite suppression on top of GLP-1 receptor effects.

Head-to-head comparison data between CagriSema and tirzepatide are not currently available. Indirect comparisons of clinical trial results suggest broadly similar efficacy ranges, though cross-trial comparisons are inherently limited by differences in study populations, designs, and endpoints. Direct head-to-head studies would be needed to establish the relative efficacy and safety of these approaches.

Both approaches share the gastrointestinal side effect profile characteristic of gut hormone therapies, including nausea, vomiting, and diarrhea during dose titration. The tolerability comparison between CagriSema and tirzepatide is of significant clinical interest but has not been formally evaluated.

Pramlintide (First-Generation Amylin Analog)#

Pramlintide (marketed as Symlin) is the only amylin analog that has received regulatory approval. It was approved by the FDA in 2005 as an adjunct to mealtime insulin therapy in patients with type 1 or type 2 diabetes. It was not developed or approved for obesity treatment as a primary indication.

The structural and pharmacokinetic comparison between pramlintide and cagrilintide highlights the evolution of amylin analog technology. Pramlintide has a half-life of approximately 48 minutes, requiring injection before each meal (typically 3 times daily). Cagrilintide has a half-life of approximately 7 days due to its acylation-mediated albumin binding, requiring only once-weekly injection. This represents more than a 200-fold increase in half-life.

The clinical experience with pramlintide provided the foundational evidence that amylin receptor agonism can reduce appetite and body weight in humans. In clinical trials, pramlintide produced modest weight loss of approximately 1 to 2 kilograms over 6 months when used as an adjunct to insulin therapy. The limited weight loss was likely constrained by the short duration of action (meal-time only) and the inconvenience of multiple daily injections.

Cagrilintide was designed to overcome these limitations by providing sustained, round-the-clock amylin receptor activation through once-weekly dosing. The substantially greater weight loss observed with cagrilintide in clinical trials (up to 10.8% at 26 weeks) compared to pramlintide validates this pharmacokinetic optimization strategy.

Liraglutide#

Liraglutide (marketed as Saxenda for obesity and Victoza for type 2 diabetes) is an earlier-generation GLP-1 receptor agonist with a shorter half-life (approximately 13 hours) requiring daily injection. At the 3.0 mg daily obesity dose, liraglutide produces approximately 8% weight loss. Cagrilintide monotherapy at the 4.5 mg weekly dose produced 10.8% weight loss, suggesting comparable or potentially superior efficacy with more convenient weekly dosing.

Summary Comparison#

Clinical Positioning#

Cagrilintide's primary clinical position is not as a standalone anti-obesity agent competing directly with semaglutide or tirzepatide, but rather as the amylin component of the CagriSema combination. The value proposition of cagrilintide lies in its ability to add an independent appetite-suppressive mechanism on top of GLP-1 receptor agonism, pushing total weight loss toward levels previously achievable only with bariatric surgery. If the REDEFINE phase 3 program confirms the phase 2 findings, CagriSema would represent a significant advance in pharmacological obesity treatment by demonstrating that multi-mechanism peptide combinations can achieve surgical-level weight loss with a non-invasive treatment approach.

Related Reading#

• Cagrilintide overview and research guide
• Cagrilintide research evidence
• Cagrilintide dosing protocols